Danny Brinkley is currently the Head of Research at invoX Pharma, bringing with him a wealth of experience in pharmaceutical research and development. Prior to their current role, Brinkley held positions at Teva Pharmaceuticals, Varydose, DJB Scientific Consultancy, Novartis, and GlaxoSmithKline. Danny holds a BSc (hons) in Pharmaceutical Science from London Metropolitan University.
April, 2024 - present